



**HAL**  
open science

# Unveiling Oral Anaerobic Bacteria Outer Membrane Vesicles: A Comprehensive Systematic Review

Priscilla Castro-Vargas, Frédérique Barloy-Hubler, Luis A Acuña-Amador

► **To cite this version:**

Priscilla Castro-Vargas, Frédérique Barloy-Hubler, Luis A Acuña-Amador. Unveiling Oral Anaerobic Bacteria Outer Membrane Vesicles: A Comprehensive Systematic Review. *Odovtos*, 2024, 26 (2), pp.41-61. 10.15517/ijds.2024.59287 . hal-04563206

**HAL Id: hal-04563206**

**<https://hal.science/hal-04563206>**

Submitted on 29 Apr 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



## LITERATURE REVIEW:

### Unveiling Oral Anaerobic Bacteria Outer Membrane Vesicles: A Comprehensive Systematic Review

Descubriendo las vesículas de membrana externa de bacterias anaerobias orales:  
una revisión sistemática integral

Priscilla Castro-Vargas<sup>1</sup> <https://orcid.org/0000-0001-6333-0419>; Frédérique Barloy-Hubler<sup>2</sup> <https://orcid.org/0000-0002-8277-6034>  
Luis Acuña-Amador<sup>1</sup> <https://orcid.org/0000-0003-1009-3020>

1. Laboratorio de Investigación en Bacteriología Anaerobia, Centro de Investigación en Enfermedades Tropicales, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica.
2. Université de Rennes 1, CNRS, UMR 6553 ECOBIO, 35042 Rennes, France.

Correspondence to: Luis Acuña-Amador - [luisalberto.acuna@ucr.ac.cr](mailto:luisalberto.acuna@ucr.ac.cr)

Received: 13-II-2024

Accepted: 11-III-2024

**ABSTRACT:** Extracellular vesicles (EV) are spherical structures limited by membranes and shed by several cell types. Specifically, outer membrane vesicles (OMVs) are nanometric particles constitutively produced by Gram-negative bacteria (GNB) under different environmental conditions. OMVs are biologically active; they are loaded with selected lipids, polysaccharides, proteins, and even different types of nucleic acids. OMVs from pathogenic oral bacteria play key roles in pathogen-host interactions, constituting a possible link between oral health and systemic disease. OMVs participate in adhesion, invasion, and damage to cells, as well as in modulating the host's immune response, biofilm formation, and promotion of virulence. The objective of this systematic review was to collect, analyze and synthesize the knowledge available on literature reviews on OMVs of the most studied pathogenic oral anaerobic GNB. This information was classified into the following categories: induction of vesiculation and biogenesis, its liberation from the parental cell, content, internalization by another host cell, and the interaction with the host cell. It was found that the most studied OMVs are those of *Porphyromonas gingivalis* and *Bacteroides spp.* and, to a lesser extent, *Aggregatibacter spp.*, and *Treponema spp.* This systematic review provides a synthesis of the current knowledge regarding OMVs, with emphasis on the information available for periodontopathogens.

**KEYWORDS:** Outer membrane vesicles; Oral anaerobic bacteria; *Porphyromonas gingivalis*; *Bacteroides*; Continuing education; Systematic review.



**RESUMEN:** Las vesículas extracelulares (EV) son estructuras esféricas delimitadas por membranas y producidas por varios tipos de células. En particular, las vesículas de membrana externa (OMV) son partículas nanométricas producidas constitutivamente por bacterias Gram negativas (GNB) en diferentes condiciones ambientales. Las OMV son biológicamente activas; están cargadas de lípidos, polisacáridos, proteínas e incluso diferentes tipos de ácidos nucleicos. Las OMV de bacterias orales patógenas desempeñan papeles clave en las interacciones patógeno-hospedero, constituyendo un posible vínculo entre la salud oral y las enfermedades sistémicas. Las OMV participan en la adhesión, la invasión y el daño celular, así como en la modulación de la respuesta inmunitaria del hospedero, la formación de biopelículas y la promoción de la virulencia. El objetivo de esta revisión sistemática era recopilar, analizar y sintetizar los conocimientos disponibles sobre las OMV de las GNB anaerobias orales patógenas más estudiadas. Esta información se clasificó en las siguientes categorías: inducción de la vesiculación y biogénesis, su liberación de la célula parental, contenido, internalización por otra célula hospedadora e interacción con la célula hospedadora. Se observó que las OMV más estudiadas son las de *Porphyromonas gingivalis* y *Bacteroides spp.* y, en menor medida, *Aggregatibacter spp.* y *Treponema spp.* Esta revisión sistemática ofrece una síntesis de los conocimientos actuales sobre las OMV, haciendo hincapié en la información disponible para los periodontopatógenos.

**PALABRAS CLAVE:** Vesículas de membrana externa; Bacterias anaerobias orales; *Porphyromonas gingivalis*; *Bacteroides*; Formación continua; Revisión sistemática.

## INTRODUCTION

The oral environment is characterized by a highly diverse microbiota organized in biofilms whose composition varies depending on the anatomic site within the oral cavity (1). A dysbiosis, a switch from a commensal microbiota to a pathogenic community, can result from changes in the oral environment, host immune status and/or the introduction of keystone pathogens, microbes that can modify their environment and the microbiota composition (2). The transition from oral health to gingivitis and periodontal disease is triggered by a specific number of bacterial species, termed a «complex» (3). *Aggregatibacter actinomycetemcomitans*, and the so-called «red complex» composed of *Porphyromonas gingivalis*, *Tannerella forsythia* and *Treponema denticola* are associated with periodontitis (4-7). The chronic inflammation caused by these anaerobic Gram-negative bacteria (GNB) has been associated with systemic disease.

For example, a high GNB load in periodontitis has been associated with adverse pregnancy outcomes and preeclampsia (8), with the progression of liver disease to liver cirrhosis (9), and these periodontopathogens have been detected in coronary plaque from coronary artery disease patients (10).

As such, the link between periodontitis, periodontopathogens and systemic disease has been established (11). Several authors, in recent years, have proposed that vesicles shed by oral bacteria could be responsible for systemic disease, in particular for cardiovascular disease (12), neuroinflammatory diseases (13), and preeclampsia (14).

Extracellular Vesicles (EVs) are proteolipid bi-layered particles (15-19), secreted by eukaryotic cells (fungi (20), protozoa (21), plants (22) and mammals (23)); archaea (24); and bacteria. EVs are released under normal and pathological conditions by metabolically active cells (25).

In particular, Bacterial Extracellular Vesicles (BEVs) range between 20 and 500nm in diameter (25). BEVs were first identified in *Escherichia coli*, and later, found in *Staphylococcus aureus* (26) and in mycobacteria (27). At first considered an artifact of lysis or cell wall turnover, their release is now recognized to establish cell-to-cell communication (28).

Naturally occurring BEVs can be classified into at least three types: Cytoplasmic Membrane Vesicles (CMVs or MVs) produced by monoderm (Gram-positive) bacteria, Outer-Inner Membrane Vesicles (OIMVs) produced by diderm (Gram-negative) bacteria, and Outer Membrane Vesicles (OMVs) also produced by diderm bacteria (29). MVs (or CMVs) seem to be produced at lower quantities than the other BEVs and are implicated in stress resistance, biofilm formation and immunity (30). OIMVs are produced at very low quantities, representing for many Gram-Negative species around 1% of BEVs production. The possession of outer membranes, plasma membranes, and cytoplasmic content characterizes OIMVs. These BEVs seem to be involved in horizontal gene transfer (31). Finally, OMVs derive from the outer membrane (OM) (29).

As the study of BEVs is still challenging in terms of isolation, purification, and individual analysis (32), its classification and nomenclature is not congruent throughout literature (33). In this review, all BEVs derived from GNB are termed OMVs and their biological features will be discussed. A special emphasis will be provided on OMVs derived from oral anaerobic GNB (1). To do so, information derived from review articles about anaerobic GNB's OMVs will be analyzed,

and examples will be commented, to introduce the oral health professionals to the subject, as a first educational approach to a topic in full expansion.

## MATERIALS AND METHODS

The recommendations of PRISMA (34) were followed for the writing of this systematic review:  
SEARCH

PubMed and ScienceDirect databases were searched from the oldest records to 12/31/2023. The search was performed using the following constructs: "Outer Membrane Vesicles", "Extracellular Vesicles" or "Bacterial Membrane Vesicles" AND "Anaerobic bacteria", "*Bacteroides*", "*Capnocytophaga*", "*Fusobacterium*", "*Porphyromonas*", "*Prevotella*", "*Tannerella*" and "*Treponema*".

## SELECTION CRITERIA

Inclusion criteria were: (1) literature reviews, (2) written in English, (3) published in a peer-reviewed journal, and (4) full-text available. The exclusion criteria were: (1) it did not contain relevant information or (2) the OMVs were not a central topic in the article. Results were downloaded and duplicate records were removed.

## DATA EXTRACTION

All the information was organized in summary tables (Table S1) that included the metadata of each bibliographic review and the relevant information for the present study. Each article was evaluated independently.

**Table S1**. Summary sheet used to extract and organize the information from the articles included in the review.

Article nº
Authors:
Publication year:
Title:
DOI:
Main objective:
Obtained information: 1. Definition: 2. Production signals: 3. Biogenesis: 4. Content: 5. Exportation mechanisms: 6. Intracellular traffic: 7. Functions: 8. Study methods: 9. Other information:
Pending issues:


## DATA ANALYSIS

Information obtained from each study was organized into five categories: (1) induction of vesiculation and biogenesis, (2) release, (3) content, (4) internalization of OMVs by a host cell, and (5) interaction of the OMV with the host cell. Based on this information, a synthesis of knowledge was written in each of the sections described above.

## RESULTS

The search returned 1485 articles for inclusion in this review. After the process of selection, deduplication, and a manual review of each of the retrieved articles, a total of 54 review articles were used for this paper (Figure 1). The genera of Gram-

negative anaerobic bacteria (GNB) whose OMVs have been studied in these articles correspond to *Porphyromonas spp.*, *Bacteroides spp.*, *Aggregatibacter spp.*, *Treponema spp.*, *Fusobacterium spp.*, *Tannerella spp.*, and *Prevotella spp.*, in decreasing order of literature sources. None of the articles found had information on the OMVs of any other oral anaerobic GNB (Table 1). Notably, the only case for which an anaerobic GNB OMV was the primary topic of a review was for *Porphyromonas gingivalis* with 4 articles out of the 54 (7,4%) used in this review. The information collected from the articles was categorized into the following topics: (1) vesiculation induction and biogenesis, (2) release, (3) content, (4) trafficking and internalization of OMVs by host cells, and (5) interaction of OMVs with host cells. The information collected is detailed below.



**Figure 1.** Flow chart based on PRISMA. Information on the article selection process for the systematic review is presented, along with the reasons for exclusion. Reason 1 for exclusion was that the article did not contain relevant information and Reason 2 was that OMVs were not a central theme in the article.

**Table 1.** Articles included in this review (number and percentage) with information on OMVs produced by oral anaerobic GNB, presented by genus and with the reference number used throughout the main text of the review.

Bacterium	Number of articles	Percentage of articles	Reference in main review text
<i>Porphyromonas spp.</i>	36	66,7%	(35,36,38-45,47-49,51-54,56,58,60,62,63,65,68-73,75,76,78-80,84,86)
<i>Bacteroides spp.</i>	34	63,0%	(37,44-50,53,54,59-61,63-65,67,68,70,72-74,76-78,80-85,87-89)
<i>Aggregatibacter spp.</i>	13	24,1%	(37,48,54,59,60,66,68,75,79,84,86-88)
<i>Treponema spp.</i>	7	13,0%	(39,40,45,62,63,68,70)
<i>Fusobacterium spp.</i>	5	9,3%	(40,44,55,60,82)
<i>Tannerella spp.</i>	2	3,7%	(40,63)
<i>Prevotella spp.</i>	2	3,7%	(60,87)
Other oral anaerobic GNB	0	0%	-

## INDUCTION OF VESICULATION AND OMV BIOGENESIS

In GNB, vesicles are formed when a section of the outer membrane (OM) selectively buds, producing vesicles that encapsulate periplasmic material and detach from the OM. This results in the creation of spheroidal particles that consist of a single lipid bilayer (an outer layer rich in lipopolysaccharide (LPS) and an inner layer with more phospholipids) with a lumen (35-40).

OMVs share similar characteristics and biomolecular components to the precursor cells from which they originated (41-43). They range in size from 20 to 250nm (42, 44) and their composition reflects components of the OM and periplasm (41, 43). OMVs are produced constitutively, at low concentrations, during different growth phases and under different conditions such as in pure culture or in natural environments, whether in biofilm or not (40, 42, 45-48). The rate of OMV production varies between bacterial species, even between strains of the same species, and can also be influenced by different environmental conditions (36, 49, 50). For example, among “the red complex”, *P. gingivalis* produces the most OMVs, followed by *Tannerella forsythia* and *Treponema denticola* (40). As mentioned, vesicle production also varies considerably between strains, for example in *Bacteroides fragilis*: whereas the OMVs were formed in great volumes by some clinical isolates, they were virtually completely absent in others (49).

Some factors such as quorum sensing, population size, and hostile or stress-generating external factors affect the properties of OMVs and increase their production (38, 41, 43, 44, 51-54). For instance, under low iron/heme conditions, *P. gingivalis* OMVs exhibited high levels of the

protein HmuY, involved in heme acquisition (38). It is noteworthy that the molecular composition of naturally produced OMVs could differ from those induced by stress (42), and that OMVs can be isolated directly from the environment, particularly from aquatic environments, and have been isolated from household dust (47).

Despite initially being considered the result of cell lysis, vesiculation occurs in viable and metabolically active cells in which the integrity of the OM is not compromised (35, 51, 52). Moreover, certain OM or periplasmic proteins are more abundant in OMVs while others are completely absent (41). These observations support that vesiculation is regulated and that it would depend on environmental factors, bacterial pathogenicity, and the cellular metabolic state (36). However, experimental data to support the hypothesis that OMV biogenesis is a regulated process is lacking. Some important biological mechanisms that continue to be unknown are genes and regulatory pathways involved in OMV production, and whether or not bacterial populations coordinate OMV liberation, to cite a few open questions.

Yet, OMV biogenesis is an energy-demanding process, so it should be a tightly controlled process, well-regulated and coordinated, as it enables crucial functions for the benefit of the producer (53). Some genes increase vesiculation rates by compromising bacterial OM (44, 52, 55); for example, in *P. gingivalis* an *ompA* mutant showed hypervesiculation (56).

## OMV RELEASE

Given the OMVs heterogeneity in production rate and size, it is likely that multiple biogenesis pathways occur in different stains and even within the same bacterial cell (53, 57). It was observed that

different *P. gingivalis* strains had varied vesiculation levels, correlating to fimbrial (FimA/FimR), OmpA-like protein and GalE expression (56, 58).

OM microdomains formed during envelope biogenesis would exhibit compositional differences, with areas prone to form OMVs (36) with specific physical characteristics in terms of curvature, charge, fluidity, and/or affinity (36). As such, induction of OMV formation results from increased OM curvature, where OM and peptidoglycan (PG)-binding proteins are decreased, absent or broken (36, 42, 47, 56, 58). This mechanism may be concomitant with others that increase turgor pressure and promote OM curvature. For example, OMV production could be induced by a negatively charged molecule that induces repulsion of the OM anionic charge (47, 59, 60) and/or the physical force induced by accumulation of misfolded or overexpressed envelope proteins (47, 56).

OM curvature is also favored in regions of low fluidity, where the proportion of saturated fatty acids is higher, which is also consistent with higher proportion of fatty acids in OMV envelopes (47). Additionally, the local curvature of bacterial OM is enhanced by extracellular signals (56), related to the affinity for amphipathic substances in the extracellular medium. This mechanism may be relevant to stress-induced responses (47).

Another factor that could promote OMV biogenesis is OM curvature increase, favored by


conformation of transmembrane proteins (36, 47). Finally, decreased, or absent expression of *vacJ* and/or *yrb* genes, due to iron and sulfate depletion, leads to the accumulation of phospholipids in OM which induces a change in membrane curvature (44, 58, 61).

As a consequence of the increase in OM curvature, by the mechanisms outlined above, a budding arises and then the OM constricts forming a proteo-liposome and encapsulating contents in its lumen (36, 41, 45). Different inducers of OMV production and release should influence different biogenesis pathways and induce mechanisms for OMV liberation from its parental cell. Knowledge about OMV surface biomarkers and their differential expression is needed. Without this information, the study of biogenesis routes or the mechanism of release would be extremely difficult.

#### OMVS CONTENT

OMVs composition varies even within the same bacterial population and depends on the growth phase and environmental conditions (51, 55). However, detailed molecular analysis of OMV contents supports the idea of selective enrichment or exclusion of specific proteins, lipids and other biomolecules (47, 52, 62). Load selection mechanisms in OMVs remain incompletely understood (38, 62). A schematic representation of the content of the OMVs is presented in Figure 2.





**Figure 2.** OMVs content and structure. OMVs are enveloped by an outer membrane bilayer of Gram-negative bacteria (GNB). They contain LPS, porins, transmembrane proteins, peptidoglycan, enzymes, proteins, nucleic acids, exogenous components, and other metabolites.

In the intravesicular lumen, the content or cargo is mostly composed of OM and periplasmic proteins, and to a minor degree, inner membrane (IM) and cytoplasmic proteins, including soluble proteins, integral membrane proteins, and lipoproteins (36, 38, 40, 41, 54, 58, 63, 64). For instance, *Aggregatibacter actinomycetemcomitans* exports leukotoxin, a Type I-secreted, highly conserved repeat toxin (RTX) family-member, through OMVs (36), while TonB-dependent receptors have been found in vesicles of *T. forsythia* (40) and Type V secretion system proteins have been identified in OMVs from *Fusobacterium nucleatum* (40).

It has also been described, in OMVs lumen, genetic material including DNA, rRNA, mRNA, miRNA, lncRNA, circRNA and other small RNAs (35, 39, 51, 58, 59, 62, 65, 66). For example, small RNAs have been found in vesicles from *A. actinomycetemcomitans*, *P. gingivalis* and *T. denti-*

*cola* (39). In the case of *P. gingivalis*, chromosomal DNA, mRNA and rRNA are present in OMVs (51). Some of these biomolecules could be biologically active (62, 67), and misfolded proteins or exogenous components such as antibiotics and metal ions have also been reported (51). OMVs from *B. fragilis* exhibited inhibitory activity against other Bacteroidales through the intravesicle antimicrobial peptide Bacteroidales secreted antimicrobial proteins (BSAP) (59).

Abundant structural proteins and porins, as well as enzymes, ion channels, transporters, and proteins related to stress responses are found in most OMVs in both the lumen and outer layers (59). For instance, several hydrolytic enzymes such as glycosidases, sulfatases and proteases are contained in vesicles derived from *Bacteroides spp.* (59). Moreover, OMV envelopes may contain a specific lipid profile that differs from OM, with distinctive

differences in the LPS profile (47, 53). *P. gingivalis* synthesizes anionic LPS and neutral LPS, both of which are present in OMVs; nonetheless, lipid A was deacylated in vesicles in comparison to the OM and cardiolipin was enriched in OMVs from *A. actinomycetemcomitans* (47, 55). Likewise, OMVs contain pathogen-associated molecular patterns (PAMPs) present in the outer membranes of bacteria (52, 68). For example, *P. gingivalis* OMVs induced NF- $\kappa$ B activation and cytokine secretion such as TNF- $\alpha$ , IL-8 and IL-1  $\beta$  on monocytes and differentiated macrophages (69). These interactions with host immune cells through PAMPs provide OMVs with immunomodulatory properties.

Thus, OMVs are a rich source of antigenic determinants and other bioactive components (70-72) that could play various roles in adherence and invasion of host cells, resistance to antibiotics, biofilm formation, promotion of virulence, or have immunomodulatory effects (36, 50, 67, 73, 74). Table 2 provides more details on the virulence factors, mainly proteases and adhesins, described in oral anaerobic GNB's OMVs.

Other OMV-associated proteins may play roles in interspecies cooperation and intercellular communication (36). For instance, *P. gingivalis* OMVs loaded with HmuY may provide a source for iron and protoporphyrin IX to *P. gingivalis*, but

also to other subgingival plaque bacteria (53). Additionally, *P. gingivalis* OMVs strongly promote coaggregation between *Staphylococcus aureus* and *Candida albicans* (58).

Many scientific groups, using proteomics, have extensively studied the presence of proteins from different cell compartments. However, protein sorting for cargo into the OMV lumen is poorly understood. Additionally, the reported presence of nucleic acids in OMV's lumen is more controversial since the biological mechanism is unknown and may be the result of contamination or a random event, rather than of active transport and packaging. It has been proposed that nucleic acids could be present in OMV's lumen through the cytoplasmic route (where cytoplasmic content is trapped into OIMVs), through the periplasmic route (where nucleic acids are exported from the cytosol to the periplasm, and then packed into OMVs), and/or through an extracellular route (where OMVs reassemble in extracellular media and incorporate nucleic acids, and/or phages inject DNA into OMVs). DNA and/or RNA sequencing from individual OMVs in a population might shed light on this controversy. Moreover, whether these nucleic acids are biologically significant and can contribute to the adaptation and response from host cells interacting with oral anaerobic GNB OMVs should be further explored.

**Table 2.** OMV-associated contents in anaerobic Gram-negative bacteria (GNB).

Bacterium	Contents	Associated effect	References
	Leukotoxin	Kills human leukocytes	(36,40,41,45,60)
	Cytolethal distending toxin	Cytolethal distension in eukaryotic cells	(36,40)
<i>Aggregatibacter sp.</i>	Peptidoglycan-associated lipoprotein	N/A	(45)
	LPS	N/A	(40)
	Phosphatidylethanolamine	N/A	(40)
	Cardiolipin	N/A	(40)
	RNA	Enhanced macrophage TNF- $\alpha$ production	(40)
	Hemagglutinin	N/A	(45)
	Cellulase, Xylanase	Provide a source of carbon from digestion of non-metabolizable carbohydrate polymers	(46)
<i>Bacteroides sp.</i>	Antimicrobial peptide BSAP	Inhibitory activity against other Bacteroidales	(43,59)
	Capsular polysaccharide A	Immune modulation	(43,54,67)
	$\beta$ -lactamases	Degradation of antibiotics	(43)
<i>Fusobacterium sp.</i>	Histamine and GABA	N/A	(83)
	Type V secretion system proteins	N/A	(40)
	Gingipains (proteases)	Cytokine degradation, tissue destruction, bacterial colony formation	(40,41,43,45,47,58,60,69)
	Fimbriae	Mediation of bacterial adherence and entry to cells	(40,45,69)
	Peptidylarginine deiminase	Citrullination of bacterial and host proteins	(40,43)
<i>Porphyromonas sp.</i>	Anionic LPS and neutral LPS	N/A	(45,47,53,55,56,58,69)
	Muramic acid	N/A	(45,69)
	Capsule	N/A	(45,69)
	Hemagglutinin	N/A	(56)
	Heme binding and transporting proteins	Heme acquisition	(40,53,58)
	DNA fragments encoding fimbriae, superoxide dismutase, and gingipains	N/A	(56)
	RNA	N/A	(39,40,51,56,58,69)
<i>Tannerella sp.</i>	Glycoproteins	N/A	(40)
	Type IX secretion system substrates	N/A	(40)
	TonB-dependent receptor	N/A	(40)
	RNA and DNA	N/A	(40)
	Dentilisin	Proteolysis and adhesion	(45)
<i>Treponema sp.</i>	RNA and DNA	N/A	(40)

BSAP: Bacteroidales secreted antimicrobial proteins; DNA: Deoxyribonucleic acid; LPS: Lipopolysaccharides; RNA: Ribonucleic acid; TNF: Tumor necrosis factor; N/A: not available.

## INTERNALIZATION OF OMVS BY A HOST CELL

Once released, OMVs can travel to distant sites and interact with various cells; this has been studied mainly in pathogenic anaerobic GNB. OMVs lack a mechanism to self-target cells and the medium they are in would affect their transport (36, 47). Several factors have been identified to promote OMVs adhesion to eukaryotic cells, such as LPS-binding proteins (47). In the case of *P. gingivalis*, fimbriae confer adhesive abilities to OMVs, and *T. denticola* OMVs also contain adhesins such as dentilisin (45).

A few routes for OMV entry into host cells have been proposed: (1) endocytosis, in eukaryotic cells it can be clathrin- or caveolin-dependent, (2) pinocytosis, an actin-induced process where nonspecific uptake of extracellular components occur, (3) by lipid rafts in the host plasma membrane via caveolins or GTPases, (4) phagocytosis, and (5) by direct membrane fusion (37-40, 43, 44, 47, 53, 54, 56, 58, 60, 63, 66-69, 74-80). In that sense, OMVs have an intrinsic ability to fuse with the cell and spill their contents into the host's cytoplasm (39, 47, 68, 69, 81).

Importantly, OMVs size and content have been shown to influence the route and speed of uptake, with potentially several endocytic pathways in simultaneous use (58, 75, 76, 78, 82). For example, rough OMVs with shorter LPS will rapidly fuse to the host membrane surface, whereas smooth OMVs, containing LPS with O-terminal antigen-terminal chains, tend to retain their spherical shape during interaction (76).

Furthermore, for pathogens with an intracellular (facultative) lifestyle, OMVs can be released directly into the host cell without the need to overcome a cytoplasmic membrane. Therefore, host responses are likely to differ according to pathogen lifestyle and interaction pathway (39).

Additionally, OMVs from bacteria can be detected in host's blood and urine. This suggests that OMV can cross the epithelium and vascular endothelium to reach sites far beyond the location of the parental cell (77). For instance, OMVs from *P. gingivalis* can relocate to blood and act on distant tissues and organs (58). In addition, histamine and  $\gamma$ -aminobutyric acid (GABA) were found in *B. fragilis* OMVs, as neurotransmitters, these compounds play a prominent role in the functions of the central nervous system (83). Thereby, OMVs can play a role in homeostasis and systemic diseases.

To travel, OMVs can use two distinct pathways: the paracellular or transcellular pathways (37, 77). The paracellular pathway works through the disruption of tight junctions (TJ) that form the intercellular barrier between epithelial cells; and the transcellular pathway consists in OMVs being internalized through endocytosis, transported through the cell body and released at the basolateral cell surface (37, 43, 77). For example, OMVs produced by *Bacteroides thetaotaomicron* have been reported to travel by both pathways, with imaging techniques showing that after hours of oral administration of OMVs, they can be detected in tissues such as the liver (77). These results support the possibility that OMVs can act as a long-distance communication system between anaerobic bacteria and the host.

It has been described that OMVs from *P. gingivalis* can be internalized via receptors, such as integrin  $\alpha 5\beta 1$ , via lipid rafts and via caveolin/clathrin-independent endocytosis (40, 53, 56, 58, 68, 76). OMVs from *P. gingivalis* have been shown to enter cells such as human oral keratinocytes and gingival fibroblasts more efficiently than parental bacterial cells (69). Moreover, the content of *T. denticola* OMVs can be sensed by the absent in melanoma 2 (AIM2) inflammasome and consequently trigger an inflammatory cell death (63).

Limited information about receptors for internalization and the actual entry route skew our understanding on anaerobic GNB OMVs entry into cells. Furthermore, a bias exists in the lack of information for almost all oral anaerobic GNB (*P. gingivalis* being perhaps the exception), as they are not usually recognized as bacterial models of study, and therefore their particularities are poorly understood.

#### INTERACTION OF OMVS WITH HOST CELLS

Host cells can internalize OMVs released by an oral anaerobic GNB. Nonetheless, host cells can be distant from where the OMVs parental cell is located. There is evidence that points that, in animals, OMVs could be dispersed in body fluids (36, 71, 77). The host cells that internalize OMVs can be bacterial or eukaryotic, as detailed below.

#### OMVS-BACTERIA INTERACTIONS

OMVs play an important role in competitive and cooperative functions for the microorganisms that secrete them, and for the microbial community by participating in events such as: i. biofilm formation, ii. gene transfer, iii. antibiotic resistance, and iv. phage neutralization (35, 36, 38-40, 42, 50, 59, 73, 75, 76, 84, 85).

i. OMVs play their role in biofilm formation and stabilization by participating in nutrient acquisition, protection against antimicrobial effects, nucleation, and intercellular communication (35, 41, 75). It has even been reported that OMVs can be part of the biofilm matrix and are one of the most important protein sources for the matrix of certain biofilms (35, 47, 76). For example, under starvation conditions, quorum sensing and the HmuY protein detected in OMVs of *P. gingivalis* aid in cell survival and biofilm formation (36, 75).

ii. OMVs could participate in the lateral transfer of plasmids and genomic DNA to other bacteria (35, 37, 47, 59, 75, 76). Gene transfer via OMVs contributes to the propagation of factors necessary for bacterial adaptation, such as antimicrobial resistance genes or virulence factors (35, 51, 59, 62, 75). For example, chromosomal DNA transfer by OMVs from two different strains of *P. gingivalis* with subsequent integration by homologous recombination and gene expression in the recipient strain has been demonstrated (51).

iii. OMVs can protect bacteria from antibiotics in several ways: (1) by carrying  $\beta$ -lactamases (36, 43, 67, 75-77), (2) by binding antibiotics in the extracellular environment, serving as a decoy, and preventing cellular entry (38, 41, 43, 59, 75, 76), and (3) by exhibiting a high content of drug-binding proteins (75). In a mixed bacterial population, OMVs may provide antibiotic protection not only to parental cells, but to the whole bacterial population; thus, OMVs may be involved in the emergence of drug-resistant strains (36, 75). For example,  $\beta$ -lactamases associated with OMVs from *Bacteroides sp.* provide antibiotic resistance to parental cells, but also to other commensals and pathogens against  $\beta$ -lactam antibiotics (43, 59, 67).

iv. Since OMVs have similar surface structures to the parental bacteria, the release of OMVs may act as a trap to prevent phage adsorption (75). Phages form complexes with OMVs and avoid binding to bacterial cells, preventing harmful effects on bacteria (59, 75).

Other functions of OMVs have been described; for example, they could be a removal system for unnecessary or harmful substances that accumulate in microbial cells, such as misfolded proteins and xenobiotics (47, 76). A graphical

summary of these and other functions performed by OMVs is presented in Figure 3.

#### OMVS-EUKARYOTIC CELL INTERACTIONS

OMVs of pathogens and commensals play a pivotal role in the communication between bacteria and their eukaryotic hosts (54, 59, 61, 86). Generally, OMVs of pathogenic and commensal bacteria are related to distinct interactions with the host: i. OMVs of commensal bacteria promote host homeostasis, and ii. OMVs of pathogenic bacteria participate in the pathological process (49, 59, 86, 87).

#### OMVS FROM COMMENSAL BACTERIA-EUKARYOTIC CELL INTERACTIONS

OMVs from commensal bacteria can generate positive effects on host immune tolerance by regulating the host innate immune system, assisting in the maturation of the immune system, and promoting homeostasis (51, 59, 61, 75, 87, 88). For example, OMVs would serve to control bacterial populations by loading with toxic molecules, such as peptidoglycan hydrolases, murein hydrolases, endopeptidases, and other types of enzymes that induce bacterial lysis, thus controlling bacterial overgrowth (46, 59, 61, 76). In addition, OMVs from commensal intestinal bacteria promote regulatory T cells and anti-inflammatory cytokine secretion through activation of host dendritic cells (DCs) (61, 70, 78).

The interaction between oral anaerobic GNB OMVs and eukaryotic cells is not fully known, many aspects need clarification, as stated throughout this review. In this sense, OMVs potentialities, especially for those produced by commensal anaerobic GNB, as drug-delivery systems or other biotechnological/biomedical uses are still too poorly understood for clinical applications.

#### OMVS FROM PATHOGENIC BACTERIA-EUKARYOTIC CELL INTERACTIONS

The content of OMVs of pathogenic bacteria is involved in host cell invasion, nutrient acquisition, antibiotic resistance, immune modulation, virulence, biofilm formation and intracellular communication (35, 36, 54, 56, 58-60, 75, 76). In addition to transferring toxins to host cells, OMVs contribute to pathogen survival and maintenance of pathogenesis by evading host immunity, aiding adaptation to the stressful environment, and nutrient capture (75). Some examples of virulence factors and their interaction with the host are cited in Table 2.

OMVs from different bacteria, and their components, induce distinct immune responses (84). LPS derived from OMVs activates toll-like receptor 4 (TLR4), which triggers inflammation through the nuclear factor kappa-light-chain-enhancer of activated B cells (NF- $\kappa$ B), proinflammatory cytokine production, caspase-11-dependent effector responses and cell death (35, 63, 68, 75, 78). Moreover, OMVs polysaccharides activate TLR2 and cytosolic nucleotide-binding oligomerization domain-containing protein 2 (NOD2), which induces phagocytosis and anti-inflammatory responses associated with autophagy (44, 63). Finally, flagellin in OMVs is detected by the nucleotide-binding domain leucine-rich repeat (NLR) family, apoptosis inhibitory protein 5 (NAIP5) and activates the NLR family CARD domain-containing protein 4 (NLRC4) inflammasome, while OMV-derived dsDNA promotes the formation of the AIM2 inflammasome; both inflammasomes trigger caspase-1-mediated pyroptosis and inflammation (44).

An example is *P. gingivalis* OMVs which can induce inflammasome activation via caspase-1 activation and IL-1 $\beta$  and IL-8 production (58, 63, 69), and induce the production of tumor necrosis factor alpha (TNF- $\alpha$ ), IL-12p70, IL-6, IL-10, inter-


feron beta (IFN $\beta$ ) and nitric oxide in macrophages (58, 69). In addition, gingipains in *P. gingivalis* OMVs induce IL-8 scission and activation, leading to neutrophil recruitment (84). Importantly, it has been reported that inflammation may be enhanced in macrophages exposed to *P. gingivalis* OMVs compared to inflammation induced by exposure to *P. gingivalis* cells (69).

The involvement of *P. gingivalis* OMVs in several diseases has been described, for example in: (1) periodontitis: OMVs induce inflammation and tissue destruction, (2) diabetes: OMVs translocate to the liver and attenuate insulin sensitivity and glycogen synthesis, (3) arteriosclerosis: OMVs possess potent platelet aggregation activity, stimulate foam cell formation and low-density lipoprotein (LDL) aggregation, (4) rheumatoid arthritis: OMVs induce production of anti-citrullinated protein antibodies and loss of tolerance to citrullinated proteins, (5) Alzheimer's disease: OMVs induce brain inflammation (40, 58, 69, 79).

For other pathogens, the amount of information found is more limited. In the case of *T.*

*denticola*, its OMVs could destroy the integrity of the epithelial cell barrier (68, 70). *F. nucleatum* OMVs activate TLR2-MyD88-NF- $\kappa$ B signaling through the FomA porin, and thus exert proinflammatory effects and regulate innate immunity (44). Finally, *A. actinomycetemcomitans* OMVs contain cytolethal distending toxin and leukotoxin A, the latter of which is lethal to human monocytes and polymorphonuclear leukocytes, and the genetic material contained in OMVs could regulate human macrophage gene expression, promoting TNF- $\alpha$  production (40, 45, 87).

Limited information about OMVs cargo is presented in the literature that presents regulation of eukaryotic cells after OMVs content's internalization. Besides the examples presented, and to add to the controversy about the presence of nucleic acids in OMVs, several studies presented downregulation of immune effectors after delivery of small RNAs into host cells by OMVs from *A. actinomycetemcomitans*, *P. gingivalis*, *T. denticola*, and/or *T. forsythia*. The lack of genetic tools to inhibit vesiculation to understand OMVs implication in infections is a difficulty that should be addressed.



**Figure 3.** OMVs functions. OMVs play several roles in bacteria-bacteria interactions in processes of cooperation and competition, and in bacteria-eukaryotic interactions either in homeostasis or pathology.

## CONCLUDING REMARKS AND PERSPECTIVES

OMVs fulfill several roles in bacteria-bacteria interactions and bacteria-eukaryotic interactions. This systematic review offers a synthesis of current knowledge available for the OMVs produced by oral anaerobic GNB. Induction of OMVs production, its biogenesis, contents, liberation from the parental cell, spread to the environment, internalization by either bacterial or eukaryotic host cells and the interactions with host cells are discussed. An important limitation in literature is the lack of consistent nomenclature for BEVs produced by GNB as at least two different types have been described: OIMVs, and OMVs. In this review, we termed OMVs both types, as almost all analyzed articles named them as such, and did not state which type of BEV was being discussed. This is the fundamental source of confusion in

the understanding of important mechanisms for OMVs cargo loading. Additionally, many aspects of OMVs biology are still poorly described: biogenesis pathways, signaling for release, receptors in the target cell, and mechanism for host cells to respond. This hinders concluding whether a specific OMV cargo has meaningful biological value to explore or is the result of contamination. As a result, contradictory results between different working groups exist, and several authors have clear positions on aspects regarding OMVs. This article is not intended to be a critical review, but rather to present the information as it is stated, and to be an invitation for the curious and informed readers to draw their own conclusions.

Nonetheless, literature describes that OMVs derived from pathogenic bacteria, like *P. gingivalis*, contain virulence factors and have inflammatory



and immunomodulatory properties. For example, *P. gingivalis* OMVs can be the cause of IL-10 secretion (anti-inflammatory) by macrophages (69).

However, some genera have very limited information while other dominates literature (*P. gingivalis*). Given the heterogeneity of OMVs, the characteristics of every species' OMVs should be studied independently; therefore, there is still a broad field of research to be developed. Considering that several of the included studies were published in recent years, this subject is in constant development, and it would be worth updating the knowledge synthesis often.

The understanding of OMVs, their nature and their interactions in a biosystem not only deepens our comprehension of the bacterial reality, but also clears the path to their biotechnological use. The development of the field has the potential for vaccine production, adjuvant platforms, antibacterial treatment, biofilm studies, drug delivery, and more. Further studies are necessary to assure safe use of OMVs in the prevention and treatment of infection and disease. Finally, the study of OMVs produced by oral anaerobic GNB is also important for broadening our comprehension of mucosal immunity as commensal and pathogenic bacteria produce them.

#### FUNDING DETAILS

P.C.V. and L.AA. were supported by Vicerrectoría de Investigación from Universidad de Costa Rica (VI-UCR) under grant 803-B9-455. VI-UCR had no role in study design, collection, analysis, interpretation of data, nor in writing the manuscript.

#### DISCLOSURE STATEMENT

The authors declare that they have no competing interests.

#### AUTHOR CONTRIBUTIONS STATEMENT

Formal analysis, Data curation, Writing-original Draft, Visualization: P.C.V.

Data curation, Writing-review & editing, Supervision: F.B.H.

Conceptualization, Methodology, Validation, Writing-review & editing, Supervision: L.A.A.

#### DATA AVAILABILITY

Data will be made available on request.

#### REFERENCES

1. Barboza-Solís C., Acuña-Amador L. The Oral Microbiota: A Literature Review for Updating Professionals in Dentistry. Part I. Odovtos-International Journal of Dental Sciences. 2019 Oct 1; 22 (1): 143-52.
2. Barboza-Solís, C., & Acuña-Amador, L. A. (2021). The oral microbiota: A literature review for updating profesional s in dentistry-Part II. Odovtos International Journal of Dental Sciences, 23 (3), 45-56. <http://dx.doi.org/10.15517/ijds.2021.45330>
3. Holt S.C., Ebersole J.L. Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia: the 'red complex', a prototype polybacterial pathogenic consortium in periodontitis. Periodontol 2000. 2005 Jun 21; 38 (1): 72-122.

4. da Silva-Boghossian C.M., do Souto R.M., Luiz R.R., Colombo A.P.V. Association of red complex, *A. actinomycetemcomitans* and non-oral bacteria with periodontal diseases. *Arch Oral Biol.* 2011 Sep; 56 (9): 899-906.
5. Buonavoglia A., Latronico F., Pirani C., Greco M.F., Corrente M., Prati C. Symptomatic and asymptomatic apical periodontitis associated with red complex bacteria: clinical and microbiological evaluation. *Odontology.* 2013 Jan 6; 101 (1): 84-8.
6. Suzuki, N., Yoneda, M., & Hirofuji, T. (2013). Mixed red-complex bacterial infection in periodontitis. *International journal of dentistry*, 2013. <https://doi.org/10.1155/2013/587279>
7. Lanza E., Magan-Fernandez A., Bermejo B., de Rojas J., Marfil-Alvarez R., Mesa F. Complementary clinical effects of red complex bacteria on generalized periodontitis in a caucasian population. *Oral Dis.* 2016 Jul 26; 22 (5): 430-7.
8. Mahendra J., Mahendra L., Sharma V., Alamoudi A., Bahammam H.A., Mugri M.H., et al. Red-Complex Bacterial Levels in Pregnant Women With Preeclampsia and Chronic Periodontitis. *Int Dent J.* 2023 Aug; 73 (4): 503-10.
9. Nagao, Y., & Tanigawa, T. (2019). Red complex periodontal pathogens are risk factors for liver cirrhosis. *Biomedical reports*, 11 (5): 199-206. <https://doi.org/10.3892/br.2019.1245>
10. Mahendra J., Mahendra L., Felix J., Romanos G.E. Genetic analysis of *P. orphyromonas gingivalis* (*fimA*), *Aggregatibacter actinomycetemcomitans*, and red complex in coronary plaque. *J Investig Clin Dent.* 2014 Aug 27; 5 (3): 201-7.
11. Guo J., Lin K., Wang S., He X., Huang Z., Zheng M. Effects and mechanisms of *Porphyromonas gingivalis* outer membrane vesicles induced cardiovascular injury. *BMC Oral Health.* 2024 Jan;24(1):112.
12. Guo J., Lin K., Wang S., He X., Huang Z., Zheng M. Effects and mechanisms of *Porphyromonas gingivalis* outer membrane vesicles induced cardiovascular injury. *BMC Oral Health.* 2024 Jan; 24 (1): 112.
13. Ha J.Y., Seok J., Kim S.J., Jung H.J., Ryu K.Y., Nakamura M., et al. Periodontitis promotes bacterial extracellular vesicle-induced neuroinflammation in the brain and trigeminal ganglion. Philpott DJ, editor. *PLoS Pathog.* 2023 Oct; 19 (10): e1011743.
14. Wang, Z., Cui, L., Nan, Y., Liu, J., & Li, C. (2023). Periodontitis & preeclampsia: were outer membrane vesicles a potential connection?. *The Journal of Maternal-Fetal & Neonatal Medicine*, 36 (1): 2183767. <https://doi.org/10.1080/14767058.2023.2183767>
15. Visan K.S., Wu L.Y., Voss S., Wuethrich A., Möller A. Status quo of Extracellular Vesicle isolation and detection methods for clinical utility. *Semin Cancer Biol.* 2023 Jan; 88: 157-71.
16. Rayamajhi S., Sulthana S., Ferrel C., Shrestha T.B., Aryal S. Extracellular vesicles production and proteomic cargo varies with incubation time and temperature. *Exp Cell Res.* 2023 Jan; 422 (2): 113454.
17. Woith E., Fuhrmann G., Melzig M.F. Extracellular Vesicles-Connecting Kingdoms. *Int J Mol Sci.* 2019 Nov 14; 20 (22): 5695.
18. Brown L., Wolf J.M., Prados-Rosales R, Casadevall A. Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi. *Nat Rev Microbiol.* 2015 Oct 1; 13 (10): 620-30.
19. Deatherage B.L., Cookson B.T. Membrane Vesicle Release in Bacteria, Eukaryotes, and

- Archaea: a Conserved yet Underappreciated Aspect of Microbial Life. Andrews-Polymenis HL, editor. *Infect Immun*. 2012 Jun; 80 (6): 1948-57.
20. Liebana-Jordan M., Brotons B., Falcon-Perez J.M., Gonzalez E. Extracellular Vesicles in the Fungi Kingdom. *Int J Mol Sci*. 2021 Jul 5; 22 (13): 7221.
  21. Sabatke B., Gavinho B., Coceres V., de Miguel N., Ramirez M.I. Unveiling the role of EVs in anaerobic parasitic protozoa. *Mol Immunol*. 2021 May; 133: 34-43.
  22. Lian M.Q., Chng W.H., Liang J., Yeo H.Q., Lee C.K., Belaid M., et al. Plant-derived extracellular vesicles: Recent advancements and current challenges on their use for biomedical applications. *J Extracell Vesicles*. 2022 Dec 15; 11 (12): 12283.
  23. Lin C., Guo J., Jia R. Roles of Regulatory T Cell-Derived Extracellular Vesicles in Human Diseases. *Int J Mol Sci*. 2022 Sep 23; 23 (19): 11206.
  24. Liu J., Cvirkaite-Krupovic V., Commere P.H., Yang Y., Zhou F., Forterre P., et al. Archaeal extracellular vesicles are produced in an ESCRT-dependent manner and promote gene transfer and nutrient cycling in extreme environments. *ISME J*. 2021 Oct 26; 15 (10): 2892-905.
  25. Ñahui Palomino R.A., Vanpouille C., Costantini P.E., Margolis L. Microbiota-host communications: Bacterial extracellular vesicles as a common language. *Oh J*, editor. *PLoS Pathog*. 2021 May 13; 17 (5): e1009508.
  26. Chen, J., Zhang, H., Wei, B., Wu, Q., & Wang, H. (2022). Inhibitors of bacterial extracellular vesicles. *Frontiers in Microbiology*, 13: 835058. <https://doi.org/10.3389/fmicb.2022.835058>
  27. Gupta, S., & Rodriguez, G. M. (2018). Mycobacterial extracellular vesicles and host pathogen interactions. *Pathogens and disease*, 76 (4): fty031. doi: 10.1093/femspd/fty031
  28. O'Donoghue E.J., Krachler A.M. Mechanisms of outer membrane vesicle entry into host cells. *Cell Microbiol*. 2016 Nov; 18 (11): 1508-17.
  29. Gill S., Catchpole R., Forterre P. Extracellular membrane vesicles in the three domains of life and beyond. *FEMS Microbiol Rev*. 2019 May 1; 43 (3): 273-303.
  30. Cao Y., Lin H. Characterization and function of membrane vesicles in Gram-positive bacteria. *Appl Microbiol Biotechnol*. 2021 Mar 6; 105 (5): 1795-801.
  31. Pérez-Cruz C., Delgado L., López-Iglesias C., Mercade E. Outer-Inner Membrane Vesicles Naturally Secreted by Gram-Negative Pathogenic Bacteria. Rudel T, editor. *PLoS One*. 2015 Jan 12; 10 (1): e0116896.
  32. Castillo-Romero K.F., Santacruz A., González-Valdez J. Production and purification of bacterial membrane vesicles for biotechnology applications: Challenges and opportunities. *Electrophoresis*. 2023 Jan; 44 (1-2): 107-24.
  33. van der Pol E., Böing A.N., Gool E.L., Nieuwland R. Recent developments in the nomenclature, presence, isolation, detection and clinical impact of extracellular vesicles. *Journal of Thrombosis and Haemostasis*. 2016 Jan; 14 (1): 48-56.
  34. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., & Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *Bmj*. 372. <https://doi.org/10.1136/bmj.n71>
  35. Ofir-Birin Y., Heidenreich M., Regev-Rudzki N. Pathogen-derived extracellular vesicles coordinate social behaviour and host manipulation. *Semin Cell Dev Biol*. 2017 Jul; 67: 83-90.
  36. Bonnington K.E., Kuehn M.J. Protein selection and export via outer membrane vesicles. *Biochimica et Biophysica Acta (BBA)- Molecular Cell Research*. 2014 Aug; 1843 (8): 1612-9.

37. Jahromi L.P., Fuhrmann G. Bacterial extracellular vesicles: Understanding biology promotes applications as nanopharmaceuticals. *Adv Drug Deliv Rev.* 2021 Jun; 173: 125-40.
38. Klimentová J., Stulík J. Methods of isolation and purification of outer membrane vesicles from gram-negative bacteria. *Microbiol Res.* 2015 Jan; 170: 1-9.
39. Lécrivain A.L., Beckmann B.M. Bacterial RNA in extracellular vesicles: A new regulator of host-pathogen interactions? *Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms.* 2020 Jul; 1863 (7): 194519.
40. Ma, L., & Cao, Z. (2021). Membrane vesicles from periodontal pathogens and their potential roles in periodontal disease and systemic illnesses. *Journal of Periodontal Research*, 56 (4): 646-655. <https://doi.org/10.1111/jre.12884>
41. Baker J.L., Chen L., Rosenthal J.A., Putnam D., DeLisa M.P. Microbial biosynthesis of designer outer membrane vesicles. *Curr Opin Biotechnol.* 2014 Oct; 29 (1): 76-84.
42. Jiang L., Schinkel M., van Essen M., Schifflers R.M. Bacterial membrane vesicles as promising vaccine candidates. *European Journal of Pharmaceutics and Biopharmaceutics.* 2019 Dec; 145 (September):1-6.
43. Doré E., Boilard E. Bacterial extracellular vesicles and their interplay with the immune system. *Pharmacol Ther.* 2023 Jul; 247: 108443.
44. Long Q., Zheng P., Zheng X., Li W., Hua L., Yang Z., et al. Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy. *Adv Drug Deliv Rev.* 2022 Jul; 186: 114321.
45. Amano A., Takeuchi H., Furuta N. Outer membrane vesicles function as offensive weapons in host-parasite interactions. *Microbes Infect.* 2010 Oct; 12 (11): 791-8.
46. Miller S.I., Bader M., Guina T. Bacterial Vesicle Formation as a Mechanism of Protein Transfer to Animals. *Cell.* 2003 Oct; 115 (1): 2-3.
47. Toyofuku M., Tashiro Y., Hasegawa Y., Kurosawa M., Nomura N. Bacterial membrane vesicles, an overlooked environmental colloid: Biology, environmental perspectives and applications. *Adv Colloid Interface Sci.* 2015 Dec; 226: 65-77.
48. Huang J., Wang X., Wang Z., Deng L., Wang Y., Tang Y., et al. Extracellular vesicles as a novel mediator of interkingdom communication. *Cytokine Growth Factor Rev.* 2023 Oct; 73: 173-84.
49. Pumbwe L., Skilbeck C.A., Wexler H.M. The *Bacteroides fragilis* cell envelope: Quarterback, linebacker, coach-or all three? *Anaerobe.* 2006 Oct; 12 (5-6): 211-20.
50. Gurunathan S., Kim J.H. Bacterial extracellular vesicles: Emerging nanoplatfroms for biomedical applications. *Microb Pathog.* 2023 Oct; 183: 106308.
51. Domingues S., Nielsen K.M. Membrane vesicles and horizontal gene transfer in prokaryotes. *Curr Opin Microbiol.* 2017 Aug; 38:1 6-21.
52. Gnopo Y.M.D., Watkins H.C., Stevenson T.C., DeLisa M.P., Putnam D. Designer outer membrane vesicles as immunomodulatory systems-Reprogramming bacteria for vaccine delivery. *Adv Drug Deliv Rev.* 2017 May; 114: 132-42.
53. Gui M.J., Dashper S.G., Slakeski N., Chen Y.Y., Reynolds E.C. Spheres of influence: *Porphyromonas gingivalis* outer membrane vesicles. *Mol Oral Microbiol.* 2016 Oct; 31 (5): 365-78.
54. Schuh C.M.A.P., Cuenca J., Alcayaga-Miranda F., Khoury M. Exosomes on the border of species and kingdom intercommunication. *Translational Research.* 2019 Aug; 210: 80-98.
55. Li D., Zhu L., Wang Y., Zhou X., Li Y. Bacterial outer membrane vesicles in cancer: Biogenesis, pathogenesis, and clinical application. *Biomedicine & Pharmacotherapy.* 2023 Sep; 165: 115120.
56. Xie H. Biogenesis and function of *Porphyromonas gingivalis* outer membrane vesicles.

- Future Microbiol. 2015 Sep 1; 10 (9): 1517-27.
57. Xie J., Li Q., Nie S. Bacterial extracellular vesicles: An emerging postbiotic. Trends Food Sci Technol. 2024 Jan; 143: 104275.
  58. Zhang Z., Liu D., Liu S., Zhang S., Pan Y. The Role of Porphyromonas gingivalis Outer Membrane Vesicles in Periodontal Disease and Related Systemic Diseases. Front Cell Infect Microbiol. 2021 Jan 28; 10 (January): 1-12.
  59. Shen Q., Xu B., Wang C., Xiao Y, Jin Y. Bacterial membrane vesicles in inflammatory bowel disease. Life Sci. 2022 Oct; 306: 120803.
  60. Xie J., Haesebrouck F., Van Hoecke L., Vandebroucke R.E. Bacterial extracellular vesicles: an emerging avenue to tackle diseases. Trends Microbiol. 2023 Dec; 31 (12): 1206-24.
  61. Zhao Y., Li X., Zhang W., Yu L., Wang Y., Deng Z., et al. Trends in the biological functions and medical applications of extracellular vesicles and analogues. Acta Pharm Sin B. 2021 Aug; 11 (8): 2114-35.
  62. Tsatsaronis J.A., Franch-Arroyo S., Resch U., Charpentier E. Extracellular Vesicle RNA: A Universal Mediator of Microbial Communication? Trends Microbiol. 2018 May; 26 (5): 401-10.
  63. Dhital, S., Deo, P., Stuart, I., & Naderer, T. (2021). Bacterial outer membrane vesicles and host cell death signaling. Trends in Microbiology, 29 (12): 1106-1116. <https://doi.org/10.1016/j.tim.2021.04.003>
  64. Ebner P., Götz F. Bacterial Excretion of Cytoplasmic Proteins (ECP): Occurrence, Mechanism, and Function. Trends Microbiol. 2019 Feb; 27 (2): 176-87.
  65. Wu Q.Y., Liu B.C., Ruan X.Z., Ma K.L. Intestinal microbiota-derived membrane vesicles and their role in chronic kidney disease. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2022 Oct; 1868 (10): 166478.
  66. Liu H., Li M., Zhang T., Liu X., Zhang H., Geng Z., et al. Engineered bacterial extracellular vesicles for osteoporosis therapy. Chemical Engineering Journal. 2022 Dec; 450: 138309.
  67. Barteneva N.S., Baiken Y., Fasler-Kan E., Alibek K., Wang S., Maltsev N., et al. Extracellular vesicles in gastrointestinal cancer in conjunction with microbiota: On the border of Kingdoms. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2017 Dec; 1868 (2): 372-93.
  68. Tsai Y.L., Tsai W.C., Qing Z., Chang C.J. Dichotomous effects of microbial membrane vesicles on the regulation of immunity. Medicine in Microecology. 2020 Mar; 3 (April): 100009.
  69. Okamura H., Hirota K., Yoshida K., Weng Y., He Y., Shiotsu N., et al. Outer membrane vesicles of Porphyromonas gingivalis: Novel communication tool and strategy. Japanese Dental Science Review. 2021 Nov; 57: 138-46.
  70. Mehanny M., Lehr C.M., Fuhrmann G. Extracellular vesicles as antigen carriers for novel vaccination avenues. Adv Drug Deliv Rev. 2021 Jun; 173: 164-80.
  71. Tanai A., Okamura H. The role of extracellular vesicles throughout normal pregnancy and in relation to oral bacteria. J Oral Biosci. 2021 Mar; 63 (1): 14-22.
  72. Van der Ley P., Schijns V.E. Outer membrane vesicle-based intranasal vaccines. Curr Opin Immunol. 2023 Oct; 84: 102376.
  73. Ahmed A.A.Q., McKay T.J.M. Environmental and ecological importance of bacterial extracellular vesicles (BEVs). Science of The Total Environment. 2024 Jan; 907: 168098.
  74. Xie J., Li Q., Nie S. Bacterial extracellular vesicles: An emerging postbiotic. Trends Food Sci Technol. 2024 Jan; 143: 104275.
  75. Aydar Çelik P., Derkuş B., Erdoğan K., Barut D., Blaise Manga E., Yıldırım Y., et al. Bacterial membrane vesicle functions, laboratory

- methods, and applications. *Biotechnol Adv.* 2022 Jan; 54: 107869.
76. Huang W., Meng L., Chen Y., Dong Z., Peng Q. Bacterial outer membrane vesicles as potential biological nanomaterials for antibacterial therapy. *Acta Biomater.* 2022 Mar; 140: 102-15.
77. Stentz R., Carvalho A.L., Jones E.J., Carding S.R. Fantastic voyage: the journey of intestinal microbiota-derived microvesicles through the body. *Biochem Soc Trans.* 2018 Oct 19;46 (5): 1021-7.
78. Tiku V., Tan M.W. Host immunity and cellular responses to bacterial outer membrane vesicles. *Trends Immunol.* 2021 Nov; 42 (11): 1024-36.
79. Ji N., Wang F., Wang M., Zhang W., Liu H., Su J. Engineered bacterial extracellular vesicles for central nervous system diseases. *Journal of Controlled Release.* 2023 Dec; 364: 46-60.
80. Niu G., Jian T., Gai Y., Chen J. Microbiota and plant-derived vesicles that serve as therapeutic agents and delivery carriers to regulate metabolic syndrome. *Adv Drug Deliv Rev.* 2023 May;196:114774.
81. Fuhrmann G., Neuer A.L., Herrmann I.K. Extracellular vesicles – A promising avenue for the detection and treatment of infectious diseases? *European Journal of Pharmaceutics and Biopharmaceutics.* 2017 Sep; 118: 56-61.
82. Chen L., Ou Q., Kou X. Extracellular vesicles and their indispensable roles in pathogenesis and treatment of inflammatory bowel disease: A comprehensive review. *Life Sci.* 2023 Aug; 327: 121830.
83. Dong X., Liu Y., Yang X., Li T. Extracellular vesicle miRNAs as key mediators in diet-gut microbiome-host interplay. *Trends Food Sci Technol.* 2023 Jun; 136: 268-81.
84. Liu H., Zhang Q., Wang S., Weng W., Jing Y., Su J. Bacterial extracellular vesicles as bioactive nanocarriers for drug delivery: Advances and perspectives. *Bioact Mater.* 2022 Aug;14: 169-81.
85. Moloudizargari M., Asghari M.H., Goel A. The therapeutic triad of extracellular vesicles: As drug targets, as drugs, and as drug carriers. *Biochem Pharmacol.* 2021 Oct; 192: 114714.
86. Wang D., Guan S., Lu P., Li Y., Xu H. Extracellular vesicles: Critical bilateral communicators in periphery-brain crosstalk in central nervous system disorders. *Biomedicine & Pharmacotherapy.* 2023 Apr; 160: 114354.
87. Díez-Sainz E., Milagro F.I., Riezu-Boj J.I., Lorente-Cebrián S. Effects of gut microbiota-derived extracellular vesicles on obesity and diabetes and their potential modulation through diet. *J Physiol Biochem.* 2022 May 2; 78 (2): 485-99.
88. Song M., Cui M., Fang Z., Liu K. Advanced research on extracellular vesicles based oral drug delivery systems. *Journal of Controlled Release.* 2022 Nov; 351: 560-72.
89. Xie J., Li Q., Haesebrouck F., Van Hoecke L., Vandembroucke R.E. The tremendous biomedical potential of bacterial extracellular vesicles. *Trends Biotechnol.* 2022 Oct; 40 (10): 1173-94.